Richwood Investment Advisors LLC Grows Stake in Eli Lilly and Company $LLY

Richwood Investment Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,120 shares of the company’s stock after buying an additional 55 shares during the period. Eli Lilly and Company accounts for approximately 4.6% of Richwood Investment Advisors LLC’s investment portfolio, making the stock its 5th biggest holding. Richwood Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $5,550,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $27,000. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter worth $40,000. Finally, TD Capital Management LLC raised its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Morgan Stanley cut their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $938.94.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $845.40 on Tuesday. The stock has a 50 day moving average of $735.35 and a 200 day moving average of $765.48. The company has a market capitalization of $800.14 billion, a price-to-earnings ratio of 55.25, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company posted $3.92 earnings per share. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.